アシルCoAデサチュラーゼ治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Acyl CoA Desaturase - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0361
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Acyl CoA Desaturase – Pipeline Review, H2 2019
Summary

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 8 molecules. The latest report Acyl CoA Desaturase – Pipeline Review, H2 2019, outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function. High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including β-cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Oncology, Metabolic Disorders, Central Nervous System and Genetic Disorders which include indications Non-Alcoholic Steatohepatitis (NASH), Colorectal Cancer, Obesity, Breast Cancer, Diabetes, Hepatocellular Carcinoma, Metastatic Renal Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson’s Disease, Prader-Willi Syndrome (PWS) and Steatohepatitis.

Furthermore, this report also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- The report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Overview
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Japan Tobacco Inc
Lipidio Pharmaceuticals Inc
Modulation Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Yumanity Therapeutics
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Drug Profiles
Aramchol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-0692 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDD-3898 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SCD1 for Diabetes, Obesity and Steatohepatitis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSI-4 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-3764518 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YTX-7739 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Dormant Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Discontinued Products
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) – Product Development Milestones
Featured News & Press Releases
Oct 31, 2019: Galmed Pharmaceuticals to present new data on aramchol effect on glucose metabolism, MoA and clinical results at AASLD 2019
Oct 07, 2019: Yumanity Therapeutics initiates phase 1 clinical trial of lead candidate YTX-7739 for the treatment of parkinson’s disease
Sep 26, 2019: Galmed Pharmaceuticals initiated ARMOR, a phase 3/4 registrational study of Aramchol in subjects with NASH and fibrosis
Apr 09, 2019: Galmed Pharmaceuticals announces successful completion of end of phase 2 meeting with FDA and plan for start of phase 3
Mar 12, 2019: Galmed reports positive results from pharmacokinetic split dose study of Aramchol
Dec 04, 2018: Yumanity Therapeutics announces publication of paper in Cell Reports detailing a potential new therapeutic target for the treatment of Parkinson’s Disease
Nov 13, 2018: Phase 2 data for Galmed Pharmaceuticals Aramchol in Non-Alcoholic Steatohepatitis (NASH) presented during late-breaking abstract oral session of The Liver Meeting 2018
Oct 02, 2018: Galmed Pharmaceuticals announces a late-breaking abstract on Aramchol to be presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting
Sep 05, 2018: Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson’s Disease
Apr 16, 2018: Galmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol for NASH
Mar 27, 2018: Galmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
Feb 14, 2018: Galmed Announces ARRIVE Study Data
Feb 08, 2018: Galmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference
Nov 27, 2017: Galmed Pharmaceuticals to Present at HEP DART 2017 Meeting
Nov 07, 2017: Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Galmed Pharmaceuticals Ltd, H2 2019
Pipeline by Japan Tobacco Inc, H2 2019
Pipeline by Lipidio Pharmaceuticals Inc, H2 2019
Pipeline by Modulation Therapeutics Inc, H2 2019
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Yumanity Therapeutics, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

【掲載企業】

Daiichi Sankyo Co Ltd
Galmed Pharmaceuticals Ltd
Japan Tobacco Inc
Lipidio Pharmaceuticals Inc
Modulation Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Yumanity Therapeutics

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アシルCoAデサチュラーゼ治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆